Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background Despite remarkable results with salvage standard-dose or high-dose chemotherapy ∼15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT.Patients and methods Single arm phase II trial investigating pembrolizumab 200 mg i.v. Q3weeks until disease progression in patients with relapsed GCT and no curable options. Patients age ≥18 with GCT who progressed after first-line cisplatin-based chemotherapy and after at least one salvage regimen (high-dose or standard-dose chemotherapy) were eligible. Centrally assessed programmed death-ligand 1 (PD-L1) on tumor and infiltrating immune cells was scored. Primary end point was overall response rate using immune-related response criteria. Simon two-stage design with type I error 20% and power 80% was utilized.Results Twelve male patients were enrolled. Median age was 38 years. All patients had nonseminoma. Primary site was testis (11) or mediastinum (1). Median AFP 615 (range 1-32, 760) and hCG 4 (range 0.6-37, 096). Six patients had late relapse (>2 years). Median number of previous chemotherapy regimens was 3. Six patients received prior high-dose chemotherapy. Two patients had positive PD-L1 staining (H-score 90 and 170). Median number of pembrolizumab doses was 2 (range 1-8). There were six grade 3 adverse events. No immune-related adverse events were reported. No partial or complete responses were observed. Two patients achieved radiographic stable disease for 28 and 19 weeks, respectively; both had continued rising AFP level despite radiographic stability and had negative PD-L1 staining.Conclusion This is the first reported trial evaluating immune checkpoint inhibitors in GCT. Pembrolizumab is well tolerated but does not appear to have clinically meaningful single-agent activity in refractory GCT.Clinical trial information NCT02499952.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“their corresponding tumors lacked PD-L1 expression on immunochemical staining [50].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“In the course of this study, there were no partial or complete response noted.”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“both of these patients exhibited ongoing increases in AFP levels despite radiographic stability”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“Among the total of 12 patients, only two of them experienced radiographically stable disease, which persisted for 28 and 19 weeks, respectively.”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“Higher levels of PD-L1 expression have been associated with robust responses in certain advanced solid tumors such as melanoma and lung cancer but not in others [10, 11].”
BackgroundOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 1×
“A Simon two-stage optimal design with type I error rate of 20% and power of 80% was utilized [17].”
MethodPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · cited 1×
“This might have been a short interval given our understanding that the immune checkpoint inhibitors have a median time to response of 2 months [8, 10].”
BackgroundSelf-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · cited 1×
“The expression of PD-L1 is known to be dynamic and is regulated by extrinsic signaling such as release of interferon-c by immune cells, loss of expression of tumor suppressor genes or activation of the AKT-mTOR pathway [27, 28].”
BackgroundHigh-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Self-citationKondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Cited by
Items 101–200 of 205
Immune-Related Concepts in Biology and Treatment of Germ-Cell Tumors
Chovanec, M., Giorgi, U. D., & Mego, M. (2018) · Advances in Urology · doi:10.1155/2018/3718165 · Cited by 9
Masterson, T. A., & Tagawa, S. T. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.02.028 · Cited by 9
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
Schepisi, G., Brighi, N., Cursano, M. C., Gurioli, G., Ravaglia, G., Altavilla, A., Burgio, S. L., Testoni, S., Menna, C., Farolfi, A., et al. (2019) · Journal of Oncology · doi:10.1155/2019/7317964 · Cited by 9
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers
Antar, R. M., Fawaz, C., Gonzalez, D., Xu, V. E., Drouaud, A., Krastein, J., Pio, F., Murdock, A., Youssef, K., Sobol, S. M., et al. (2024) · Current Oncology · doi:10.3390/curroncol31110511 · Cited by 10
Genomic features of mediastinal germ cell tumors: a narrative review
Özgün, G., Nichols, C. R., Kollmannsberger, C., & Nappi, L. (2022) · Mediastinum · doi:10.21037/med-22-4 · Cited by 8
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer
Bleve, S., Cursano, M. C., Casadei, C., Schepisi, G., Menna, C., Urbini, M., Gianni, C., Padova, S. D., Filograna, A., Gallá, V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910087 · Cited by 8
Current Management of Refractory Germ Cell Tumors
Abughanimeh, O. K. M., & Teply, B. A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01093-z · Cited by 7
Farahani, H., Darvishvand, R., Khademolhosseini, A., & Erfani, N. (2024) · Andrology · doi:10.1111/andr.13751 · Cited by 7
Novel therapeutics in refractory germ cell tumors
Richardson, N. H., & Adra, N. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001129 · Cited by 7
Self-citationOing, C., & Bokemeyer, C. (2018) · Current Opinion in Urology · doi:10.1097/mou.0000000000000531 · Cited by 7
Huang, T., Hung, G., Weng, T., Wang, F., Lee, C.-Y., Lin, D., Chen, B., Lin, K., Wu, K., Liu, H., et al. (2022) · Cancer · doi:10.1002/cncr.34494 · Cited by 8
Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review
Nasioudis, D., & Pashankar, F. (2024) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-005052 · Cited by 7
Promising novel therapies for relapsed and refractory testicular germ cell tumors
Kozakova, K., Mego, M., Cheng, L., & Chovanec, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1838279 · Cited by 7
Targeted Therapy in Patients with Metastatic Male Germ Cell Tumors
Heidenreich, A., Paffenholz, P., Nestler, T., Tolkach, Y., & Pfister, D. J. K. P. (2021) · Urologia Internationalis · doi:10.1159/000510717 · Cited by 7
Immune-related mechanisms and immunotherapy in extragonadal germ cell tumors
Xiu, W., Pang, J., Hu, Y., & Shi, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145788 · Cited by 16
Ricci, C., Ambrosi, F., Franceschini, T., Grillini, A., Franchini, E., Vasuri, F., Orsatti, A., Sciascio, L. D., Massari, F., Mollica, V., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04243-x · Cited by 6
Brain and Spinal Tumors Originating from the Germ Line Cells
Wong, T., Tsai, M., Chang, H. C., Hsieh, K. L., Ho, D. M., Lin, S., Yen, H., Chen, Y., Lee, H., & Yang, T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_16 · Cited by 6
Treatment of recurrent ovarian germ cell tumours: Is there a role for immune checkpoint inhibitors?
Bernard, L. (2024) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2024.101502 · Cited by 6
Wang, Y., Ji, C., Liu, J., Wang, Y., Song, N., & Cao, P. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106710 · Cited by 6
Al-Hogbani, M., Duguay, J., Wagner, D.-C., Haferkamp, A., Joubert, P., Frees, S., Rendon, R., Power, N., Périgny, M., & Toren, P. (2021) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.02.014 · Cited by 5
Single-cell profiling in ovarian germ cell and sex cord-stromal tumours
Laga, T., Rompuy, A. V., Busschaert, P., Marquina, G., Loverix, L., Olbrecht, S., Ottenbourgs, T., Baert, T., Gorp, T. V., Vergote, I. B., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03012-6 · Cited by 5
Choriocarcinoma: Diagnosis, treatment and management of a rare germ cell tumour. An update review
Pierantoni, F., Fabiana, C., Djaballah, S. A., Lai, E., Bimbatti, D., Stragliotto, S., Zampiva, I., Ballestrin, M., Chiara, P. M., Jubran, S., et al. (2026) · Tumori Journal · doi:10.1177/03008916251408266 · Cited by 6
Zhou, J., An, W., Guan, L., Shi, J., Qin, Q., Zhong, S., Huang, Z., Liu, R., Wu, C., Ma, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1536722 · Cited by 6
de Vasconcellos, V. F., Bastos, D. A., Pereira, A. A. L., Watarai, G., Pereira, B. R., de Godoy, A., Silva, J. A., Muniz, D. Q. B., Guglielmetti, G., Nahas, W. C., et al. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00170 · Cited by 5
Wang, Y., Yang, J., Yu, M. Y., Cao, D., & Shen, K. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s176854 · Cited by 5
Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coin
Rescigno, P., Ottaviano, M., & Palmieri, G. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.24 · Cited by 5
Novel treatment options for refractory Germ Cell Tumours: back to the bench!
Kollmannsberger, C., Nappi, L., & Nichols, C. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx746 · Cited by 4
Εmerging Biomarkers in the Diagnosis and Treatment of Testicular Tumors
Evmorfopoulos, K., Vlachostergios, P. J., Sountoulides, P., & Tzortzis, V. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230324114236 · Cited by 4
The effect of aromatase inhibitors against possible testis toxicity in pembrolizumab treated rats
Türkmen, N. B., Çiftçi, O., Taşlıdere, A., Aydın, M., & Eke, B. C. (2022) · Andrologia · doi:10.1111/and.14557 · Cited by 4
Upregulated HAVCR2: A Prognostic and Immune‐Related Marker in Testicular Germ Cell Tumors
Xue, L., Zhao, X., Jia, H., Xie, Y., Wen, Y., Yu, L., Liu, Z., Cao, J., Bo, H., Liu, L., et al. (2023) · Andrologia · doi:10.1155/2023/5524200 · Cited by 4
Driver mutations associated with signatures of platinum sensitivity in germ cell tumors
Sawa, Y. C., Jia, L., Krause, H. B., Meagher, M. F., Millard, F. E., Elliott, A., Lafin, J. T., Jamieson, C., Antonarakis, E. S., D'souza, A., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00727-2 · Cited by 3
Immune Checkpoint Inhibitors in Patients with Testicular Cancer: A Systematic Review
Salazar-Mejía, C. E., Villarreal-González, R. V., Vidal-Gutiérrez, Ó., Cruz, C., Guadarrama-Rendón, E., Alvarado-Ruiz, S. A., Guerra-Garza, A. S., Quiroz-Huerta, R., Salazar-Salazar, K. A., & Álvarez‐Villalobos, N. A. (2024) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2024.0056 · Cited by 4
Gargus, E. S., Kuribayashi, S., Lundy, S. D., Rotz, S. J., Alkhouli, L., Bussies, P. L., & Falcone, T. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-000843 · Cited by 6
Islam, R., Figura, M., Heyer, J., Lieber, S., Huber, M., Loveland, K. L., Schuppe, H., & Fietz, D. (2026) · Andrology · doi:10.1111/andr.70200 · Cited by 4
Tseng, J., Chen, C.-Y., Liang, C., & Huang, F. (2024) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2024.03.008 · Cited by 3
Sokołowski, M., Sokołowska, A., Chrząszcz, M., & Butrym, A. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157194 · Cited by 3
Pineal Gland Tumor Microenvironment
Choque‐Velasquez, J., Baluszek, S., Colasanti, R., Muhammad, S., & Hernesniemi, J. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_8 · Cited by 3
Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution
Lu, K. L., Chiu, K., & Cheng, C. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_7 · Cited by 3
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 8
Diagnosis and management of mediastinal extragonadal germ cell tumors
Heidenreich, A., Paffenholz, P., & Pfister, D. J. K. P. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00941-x · Cited by 4
Li, P., Zhong, Y., Zhang, M., Zheng, Y., & Peng, W. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2302 · Cited by 5
Yang, L., Shen, Y., Yan, J., Cheng, H., Feng, J., Feng, X., Chang, X., Zhu, Z., Meng, D., Zhang, X., et al. (2026) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2026.37.e81 · Cited by 2
Decoding testicular germ cell tumors: integrating risk, biology, and biomarkers into future care
Bowling, G. C., Lacson, J. C. A., Almeida, A. A., Rhee, J., Chesnut, G. T., Nichols, C. R., & Kern, S. Q. (2026) · Gene · doi:10.1016/j.gene.2026.150044 · Cited by 2
How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer
Richardson, N. H., Tewari, A. K., Giannatempo, P., Basin, M. F., Nuzzo, A., Mascaro, F., Feldman, D. R., Adra, N., & Daneshmand, S. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516212 · Cited by 2
Self-citationKim, K. H., Lee, D. Y., Yang, H. J., Kim, S. H., Kim, D. S., Lee, C. H., Hong, S. A., Chi, B. H., Lee, J. G., & Jeon, Y. S. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101278 · Cited by 3
Latest progress in molecular biology and treatment in genitourinary tumours
del Alba, A. G., Arranz, J. Á., Bellmunt, J., Maroto, P., Calvo, O. F., Valderrama, B. P., González‐Billalabeitia, E., Méndez-Vidal, M. J., Cassinello, J., Romero-Laorden, N., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02373-z · Cited by 2
Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy
Tu, S., Aydın, A. M., Maraboyina, S., Chen, Z., Singh, S. R. K., Gökden, N., & Langford, T. (2023) · Cancers · doi:10.3390/cancers15225385 · Cited by 2
Current outstanding challenges in germ cell tumors
Salous, T., & Adra, N. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001026 · Cited by 2
Self-citationvan Creij, N. C. H., Klinglmair, G., Gruber, L. N., Partl, A., Zeimet, A. G., Santer, F. R., Schnaiter, S., Mayr, R., Lackner, F., Čulig, Z., et al. (2025) · Therapeutic Advances in Urology · doi:10.1177/17562872251322648 · Cited by 2
Chahoud, J., Zhang, M., Pisters, L. L., Lin, S.-C., Lin, S.-H., & Tu, S. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.05.004 · Cited by 2
Wood, G. E., Bunting, C. P., Veli, M., Arora, R., Berney, D. M., Alifrangis, C., MacDonald, N., Miller, R. E., Shamash, J., Stoneham, S. J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1271647 · Cited by 2
Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer
Jackson, J. C., Sanchez, D., Johns, A. C., Campbell, M. T., Aydın, A. M., Gökden, N., Maraboyina, S., Muesse, J. L., Ward, J. F., Pisters, L. L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123436 · Cited by 2
An update on immunotherapy in uro-oncology
Cimadamore, A., Rizzo, A., Mollica, V., Massari, F., López-Beltrán, A., Scarpelli, M., Cheng, L., Santoni, M., & Montironi, R. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1911638 · Cited by 2
Huang, R., Shu, D., Li, H., Hu, A., Chen, M., Yang, W., Zhang, Y. X., Zheng, Q., An, X., Xue, C., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113042 · Cited by 1
Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies
Khorasanchi, A., Jatwani, K., Meng, L., Collier, K. A., Sundi, D., Dason, S., Singer, E. A., Gopalakrishnan, D., Mortazavi, A., Chatta, G. S., et al. (2024) · Cancers · doi:10.3390/cancers16244127 · Cited by 1
Khalid, F., Bodla, Z. H., Gaddameedi, S. R., Macasaet, R., Yagnik, K. J., Niaz, Z., Fish, P. N., Du, D. T., & Shah, S. Q. (2025) · Current Oncology · doi:10.3390/curroncol32020108 · Cited by 1
Glienke, M., Himmelsbach, R., Zirngibl, M., Metzger, P., Kühn, J., Miething, C., Sigle, A., Gratzke, C., Nientiedt, C., Rassner, M. P., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1688779 · Cited by 1
Caramella, I., Abeni, C., Cherri, S., Ogliosi, C., Morena, T., Galvagni, G., Meriggi, F. A., & Zaniboni, A. (2026) · Cancers · doi:10.3390/cancers18030497 · Cited by 1
Saavedra, A. L., Díaz‐Chávez, J., Jiménez-Ríos, M. Á., & Scavuzzo, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847225 · Cited by 1
Lisek, N. A., Kusiel, J. G., & Myint, Z. W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1847167 · Cited by 1
Testicular yolk sac tumour metastasis to the L2 vertebra
Murray, G., Jesús, O. D., Correa-Rivas, M. S., & Cheverez-Ocasio, J. I. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-250461 · Cited by 1
Challenges in the management of relapsed germ cell tumors
Salous, T., & Adra, N. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000933 · Cited by 1
Self-citationMetastatic Germ Cell Tumor Showing a Durable Response to the Anti-PD-1 Antibody Toripalimab
Wang, R., Wang, W., Zhang, W., & Bai, Y. (2023) · Immunotherapy · doi:10.2217/imt-2022-0228 · Cited by 1
Case Report: From epilepsy and uterus didelphys to Turner syndrome-associated dysgerminoma
Li, J., Zhu, H., Ma, X., Li, J., Xue, J., & Feng, L. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2023.1286515 · Cited by 1
Comparative analysis of testicular and nontesticular choriocarcinoma: a population-based study
Alshwayyat, S., Soudi, M. S., Qaddoura, M. T., Alshwayyat, T. A., Ababneh, O. E., Hanifa, H., Odat, R. M., & Al-Azab, R. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002702 · Cited by 1
Precision Medicine in Thoracic Surgery
Poulos, C. M., & Servais, E. L. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.07.001 · Cited by 1
No activity of pembrolizumab in phase II trial
Thoma, C. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.194
Systemic Therapies for Metastatic Testicular Germ Cell Tumors: Past, Present and Future
Parimi, S., Rauw, J. M., & Ko, J. J. (2018) · Current Cancer Therapy Reviews · doi:10.2174/1573394714666180706150427
Vicier, C., Baciarello, G., Arfi, J., Massard, C., Loriot, Y., Albiges, L. K., Cojean-Zelek, I., & Fizazi, K. S. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.010
Novel preclinical models, therapies and biomarkers for testicular cancer
Plaza, F. X. R. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.119056452
Cisplatinrefraktäre Keimzelltumoren – molekulare Grundlagen und klinische Konzepte
Bokemeyer, C., Skowron, M. A., Peters, M.-C., Nettersheim, D., & Oing, C. (2020) · Der Onkologe · doi:10.1007/s00761-020-00881-9
Manejo de los Pacientes con Tumores de Celulas Germinales en Primera Recaida
Gimón, R. V., Sucre-Márquez, C., Zalazar, H., Martinez, B., & Vivas, L. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.113
Castro, M. N. (1998) · Revista chilena de derecho privado
Paulsen, F., & Seidel, C. A. (2022) · International Journal of Urology · doi:10.1111/iju.14949
Hawking, M. K., Paner, G. P., Eggener, S. E., & Stadler, W. M. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm101.pub2
Hematopoietic Cell Transplantation for Germ-Cell Tumors and Other Adult Solid Tumors
Ramdial, J., Jankowski, M. L., & Nieto, Y. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00028-0
Güven, D. C., Aykan, M. B., Muğlu, H., Bayram, E., Helvacı, K., Dursun, B., Celayir, M., Celebiyev, E., Nayır, E., Erman, M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6869
Extragonadal germ-cell tumor presenting initially as a massive abdominal mass: A case report
Tong, J., Cui, Y., Liu, S., & Yang, X. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.01.140
Immunotherapy in Genitourinary Malignancies
Orme, J. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_11
Joshi, A., Shrirangwar, S., Kataria, P., Goel, A., & Pande, N. (2024) · Springer eBooks · doi:10.1007/978-981-99-3378-5_53
Boente, L. D. A., Noronha, F. B., de Oliveira, F. L. Q., de Oliveira, A. C. F., & de Oliveira, F. N. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15609-0.00031-3
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26578733
Lobo, J., Constâncio, V., Leite‐Silva, P., Guimarães, R., Cantante, M., Braga, I. C., Maurício, J., Looijenga, L. H. J., Henrique, R., & Jerónimo, C. (2021) · Figshare · doi:10.6084/m9.figshare.14379206
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26578727
Lobo, J., Constâncio, V., Leite‐Silva, P., Guimarães, R., Cantante, M., Braga, I. C., Maurício, J., Looijenga, L. H. J., Henrique, R., & Jerónimo, C. (2021) · Figshare · doi:10.6084/m9.figshare.14379215
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26578730
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26578736
Lobo, J., Constâncio, V., Leite‐Silva, P., Guimarães, R., Cantante, M., Braga, I. C., Maurício, J., Looijenga, L. H. J., Henrique, R., & Jerónimo, C. (2021) · Figshare · doi:10.6084/m9.figshare.14379209
Lobo, J., Constâncio, V., Leite‐Silva, P., Guimarães, R., Cantante, M., Braga, I. C., Maurício, J., Looijenga, L. H. J., Henrique, R., & Jerónimo, C. (2021) · Figshare · doi:10.6084/m9.figshare.14379212
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26578724
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26578721
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26578718
Palliative Therapie und neue Therapiekonzepte bei Keimzelltumoren
Lorch, A. (2026) · Die Onkologie · doi:10.1007/s00761-026-01904-7
Recent developments and outstanding challenges in germ cell tumors
Khalid, A. B., & Salous, T. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001228
Current problems in epidemiology, diagnosis and treatment of testicular cancer
Корчагин, М. П., Sokolov, E. A., & Pushkar, D. Y. (2026) · Cancer Urology · doi:10.17650/1726-9776-2025-21-4-186-196
Parteni, D. E., Tîrnovanu, M. C., Țarcă, E., Belu, A., Jehac, A., Lozneanu, L., Giuşcă, S. E., Ungureanu, C., Moroşan, E., & Cojocaru, E. (2026) · Cancers · doi:10.3390/cancers18101554
Oltrecolli, M., Alaimo, D., Costanzo, F. D., Rosti, G., Rescigno, P., Dominici, M., Alsdorf, W. H., Bokemeyer, C., Oing, C., & Seidel, C. A. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261451841
Tavares, N. T., Liu, M. Y., Henrique, R., Jerónimo, C., Weiss, R. S., & Lobo, J. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261446794
Kostadinova, K., Venkov, K., Tonev, I., Mincheff, M. S., Bankova, A. K., & Mihaylov, G. G. (2026) · Uro · doi:10.3390/uro6030020
Metadata
- Authors
- Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H.
- Affiliations
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (US)
- Indiana University School of Medicine (US)
- Hoosier Cancer Research Network (United States) (US)
- Abramson Cancer Center (US)
- Corresponding author
- Adra, N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 29
- Issue
- 1
- Pages
- 209-214
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2765537501
- Cited by
- 196
- References
- 28
- Citations by year
- 2026: 18 · 2025: 11 · 2024: 28 · 2023: 19 · 2022: 18 · 2021: 29 · 2020: 24 · 2019: 28 · 2018: 18
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 722 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- pembrolizumab, germ cell tumors, non-seminoma, platinum-refractory disease, immune checkpoint inhibitors, PD-L1 expression, immunotherapy, overall response rate, alpha-fetoprotein, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Biomarkers, Tumor, Salvage Therapy, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.